Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.8

Margin Of Safety %

26

Put/Call OI Ratio

0.78

EPS Next Q Diff

-0.22

EPS Last/This Y

5.39

EPS This/Next Y

-0.56

Price

54.92

Target Price

56.55

Analyst Recom

2.43

Performance Q

23.35

Relative Volume

0.79

Beta

0.29

Ticker: BMY




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26BMY54.670.940.41700214
2025-12-29BMY54.120.940.93692476
2025-12-30BMY54.230.950.24699297
2025-12-31BMY53.950.940.01707593
2026-01-02BMY53.471.101.54658349
2026-01-05BMY53.061.110.72653932
2026-01-06BMY54.441.100.14663532
2026-01-07BMY56.721.050.20681537
2026-01-08BMY55.910.980.85717601
2026-01-09BMY55.870.980.99728534
2026-01-12BMY55.781.010.36725776
2026-01-13BMY55.931.010.55727276
2026-01-14BMY57.031.010.36731655
2026-01-15BMY56.621.000.39738402
2026-01-16BMY55.271.010.41741042
2026-01-20BMY54.220.790.39534950
2026-01-21BMY54.480.790.42543583
2026-01-22BMY54.920.780.33556926
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26BMY54.670.34177.56.54
2025-12-29BMY54.120.34082.56.54
2025-12-30BMY54.230.34209.36.54
2025-12-31BMY53.950.34133.66.54
2026-01-02BMY53.480.34093.36.54
2026-01-05BMY53.060.34231.16.54
2026-01-06BMY54.450.34596.96.54
2026-01-07BMY56.720.34776.16.54
2026-01-08BMY55.91-0.24156.66.54
2026-01-09BMY55.87-0.24179.56.54
2026-01-12BMY55.78-0.24168.86.54
2026-01-13BMY55.93-3.24216.56.54
2026-01-14BMY57.01-4.54398.36.54
2026-01-15BMY56.62-4.54108.76.54
2026-01-16BMY55.26-4.53923.56.54
2026-01-20BMY54.21-7.73979.36.54
2026-01-21BMY54.49-7.74238.16.54
2026-01-22BMY54.92-11.24268.76.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26BMY-1.52-1.571.74
2025-12-29BMY-1.52-1.561.74
2025-12-30BMY-1.52-1.561.74
2025-12-31BMY-1.52-1.561.74
2026-01-02BMY-1.52-1.561.74
2026-01-05BMY-1.52-1.531.74
2026-01-06BMY-1.52-1.531.74
2026-01-07BMY-1.52-1.531.74
2026-01-08BMY-1.52-1.531.74
2026-01-09BMY-1.52-1.531.74
2026-01-12BMY-1.51-1.591.74
2026-01-13BMY-1.52-1.591.80
2026-01-14BMY-1.52-1.591.80
2026-01-15BMY-1.52-1.591.80
2026-01-16BMY-1.52-1.591.80
2026-01-20BMY-1.52-1.671.80
2026-01-21BMY-1.52-1.671.80
2026-01-22BMY-1.52-1.671.80
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

1.63

Avg. EPS Est. Current Quarter

1.68

Avg. EPS Est. Next Quarter

1.41

Insider Transactions

-1.52

Institutional Transactions

-1.67

Beta

0.29

Average Sales Estimate Current Quarter

12237

Average Sales Estimate Next Quarter

10414

Fair Value

68.99

Quality Score

83

Growth Score

48

Sentiment Score

11

Actual DrawDown %

32.6

Max Drawdown 5-Year %

-47.7

Target Price

56.55

P/E

18.55

Forward P/E

9.17

PEG

0.13

P/S

2.33

P/B

6.03

P/Free Cash Flow

7.31

EPS

2.96

Average EPS Est. Cur. Y​

6.54

EPS Next Y. (Est.)

5.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.57

Relative Volume

0.79

Return on Equity vs Sector %

5.3

Return on Equity vs Industry %

-4.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

4268.7
Bristol-Myers Squibb Company
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 34100
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
stock quote shares BMY – Bristol-Myers Squibb Company Stock Price stock today
news today BMY – Bristol-Myers Squibb Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BMY – Bristol-Myers Squibb Company yahoo finance google finance
stock history BMY – Bristol-Myers Squibb Company invest stock market
stock prices BMY premarket after hours
ticker BMY fair value insiders trading